Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

HSDT vs QNRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HSDT Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–1 Matrix Metrics)

HSDT Overall Winner 6-Pillar Tally: HSDT 4 – 1 QNRX (1 Tie) Matrix Metrics: HSDT 8 – 1 QNRX

As of Nov 19, 2026, Solana Company (HSDT) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HSDT carries a Unified Composite Score of 59.0/100 (HOLD) at $1.66 (N/M Forward P/E, -1557.5% operating margin), whereas QNRX carries 47.1/100 (HOLD) at $3.36 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: HSDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.4); meanwhile QNRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HSDT vs QNRX
HSDT NASDAQ Head-to-Head Winner
Solana Company Class A Common Stock (DE)
Electromedical & Electrotherapeutic Apparatus
$1.66
+1.84% 1D
Market Cap $103.1M
TTM Revenue $272M
Forward P/E N/M
Beta / 30D Vol 2.20β · 55% Vol
Unified Composite Score
59.0 / 100 HOLD
Tech 60.0 Fund 53.0 Flow 58.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.0%), weak momentum, RSI 29
RSI-14: 29.4 · SMA20: $1.96 · SMA50: $2.31
QNRX NASDAQ
Quoin Pharmaceuticals, Ltd. American Depositary Shares
Pharmaceutical Preparations
$3.36
-5.64% 1D
Market Cap $17.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.35β · 72% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.2%), weak momentum, RSI 34
RSI-14: 33.8 · SMA20: $3.85 · SMA50: $4.71

6-Pillar Scorecard Institutional Category Breakdown (HSDT 4 – 1 QNRX)

Columns: Metric · HSDT · QNRX
1. Valuation Multiples HSDT
Forward P/E N/M N/M
Trailing P/E 0.0x 8.1x
PEG Ratio N/M N/M
EV / Revenue 0.4x N/M
2. Growth & Scale HSDT
Revenue Growth (YoY) +382.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $272M N/A
Market Cap $103.1M $17.1M
3. Profitability & Quality HSDT
Gross Margin 92.8% N/A
Operating Margin -1557.5% 0.0%
Net Profit Margin 2040.4% 0.0%
Return on Equity (ROE) 52.8% -142.6%
4. Balance Sheet & Cash Flow HSDT
Cash Generation (TTM) -$4.22B EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.38 Book/Sh · 52.8% ROE $5.97 Book/Sh · -142.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning QNRX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 540.7% (85th %ile) N/A (N/A)
Put/Call OI Skew 7.50x (Put-Skewed) Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Asset Management Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HSDT (8) vs QNRX (1)
Institutional Metric HSDT QNRX Criterion Row Edge
Market Capitalization
Scale
$103.1M $17.1M Larger Scale HSDT
Trailing P/E Ratio
Valuation
0.0x 8.1x Lower Multiple HSDT
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+382.1% +0.0% Higher Growth HSDT
Operating Margin (TTM)
Profitability
-1557.5% 0.0% Higher Margin QNRX
Net Profit Margin
Profitability
2040.4% 0.0% Higher Margin HSDT
Return on Equity (ROE)
Capital Efficiency
52.8% -142.6% Higher ROE HSDT
52-Week Range Position
Momentum
15% ($1–$4) 0% ($3–$24) Stronger Trend HSDT
Beta / 30D Volatility
Risk Regime
2.20β · 55% Vol 1.35β · 72% Vol Lower Realized Risk HSDT
Unified Institutional Score
Composite Signal
59.0 / 100 (HOLD) 47.1 / 100 (HOLD) Higher Composite HSDT
Trailing 12M Revenue (USD)
Operating Scale
$272M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
92.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$4.22B EBITDA ($4.38 Book/Sh · 52.8% ROE) N/A ($5.97 Book/Sh · -142.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon QNRX +13.85 pp
HSDT: -29.66% · QNRX: -15.81%
3M Horizon HSDT +18.74 pp
HSDT: -20.95% · QNRX: -39.69%
6M Horizon HSDT +1.08 pp
HSDT: -29.66% · QNRX: -30.74%
1Y Horizon HSDT +24.04 pp
HSDT: -58.5% · QNRX: -82.54%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HSDT vs QNRX. Trailing 12-month operating profitability (HSDT -1557.5% vs QNRX 0.0%) and valuation multiples (HSDT N/M vs QNRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

HSDT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$272M
Gross Margin92.8%
Op. Margin-1557.5%
ROE / Fwd P/E52.8% · N/M
QNRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-142.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HSDT BREAKDOWN
42d in phase · OBV DISTRIBUTION
Current IV 540.7%
IV Percentile 85th %ile
Put/Call OI Skew 7.50x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact HSDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
QNRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact QNRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HSDT Moat Profile High-Margin Pricing Power Moat
Asset Management Operator
Competes within the Asset Management value chain with $103.1M market capitalization and -1557.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
QNRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $17.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HSDT vs QNRX Key Questions & Quantitative Answers

As of Nov 19, 2026, Solana Company (HSDT) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HSDT carries a Unified Composite Score of 59.0/100 (HOLD) at $1.66 (N/M Forward P/E, -1557.5% operating margin), whereas QNRX carries 47.1/100 (HOLD) at $3.36 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: HSDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.4); meanwhile QNRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HSDT leads the Growth & Scale pillar: HSDT posts +382.1% YoY revenue growth and +0.0% YoY earnings growth on $272M TTM revenue (92.8% gross margin, -1557.5% operating margin), compared with QNRX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, HSDT generates $272M in USD-normalized revenue versus N/A for QNRX. In operating R&D and SG&A reinvestment, HSDT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for QNRX.

HSDT screens cheaper on headline valuation multiples. HSDT trades at N/M Forward P/E, 0.0x Trailing P/E, N/M PEG, and 0.4x EV/Revenue (unreported EBITDA margin), whereas QNRX trades at N/M Forward P/E, 8.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HSDT (52.8% ROE) versus QNRX (-142.6% ROE) capital efficiency.

In options market volatility and institutional positioning, HSDT carries 540.7% implied volatility (85th %ile, Extreme (>80th %ile)), a 7.50x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.20β · 55% Vol realized risk). By comparison, QNRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 72% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.